$15.5 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$119.29 - $178.41The lowest and highst price in the last 52 weeks.
-17.72xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$15.5 Billion|
|Enterprise Value||$13.8 Billion|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||-9.1%|
|Outstanding Shares||118 Million|
|Avg 30 Day Volume||512 Thousand|
|Earnings per Share||-$7.55|
|Price to Sales Ratio||43.77|
|Price to Book Ratio||16.41|
|Revenue to Enterprise Value||31.56|
|EBIT to Enterprise Value||-15.36|
|Total Debt to Enterprise Value||0.01|
|Debt to Equity||0.19|
|Gross Profit||$370 Million|
|Net Income||-$881 Million|
|Quarterly Earnings Growth (YoY)||-11.8%|
|Return on Equity||-86.71%|
|Return on Assets||-25.86%|
|Return on Invested Capital||-31.94%|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 10th A...Business Wire, 3 months ago
Chardan Capital Stick to Their Buy Rating for Alnylam PharmaceuticalsInvesting.com, 3 months ago
Oppenheimer Stick to Their Hold Rating for Alnylam PharmaceuticalsInvesting.com, 3 months ago